A Study to Evaluate the Safety and Effectiveness of Doxercalciferol Capsules in Participants With Moderate to Severe Psoriasis
Public ClinicalTrials.gov record NCT00601107. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Efficacy and Safety of Doxercalciferol Capsules in the Treatment of Subjects With Moderate to Severe Chronic Plaque Psoriasis
Study identification
- NCT ID
- NCT00601107
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Enrollment
- 111 participants
Conditions and interventions
Conditions
Interventions
- Doxercalciferol Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2008
- Primary completion
- Jan 31, 2009
- Completion
- May 31, 2009
- Last update posted
- May 4, 2014
2008 – 2009
United States locations
- U.S. sites
- 19
- U.S. states
- 16
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | — | — |
| Not listed | Hot Springs | Arizona | — | — |
| Not listed | Little Rock | Arkansas | — | — |
| Not listed | Irvine | California | — | — |
| Not listed | Santa Monica | California | — | — |
| Not listed | Alpharetta | Georgia | — | — |
| Not listed | Indianapolis | Indiana | — | — |
| Not listed | Andover | Massachusetts | — | — |
| Not listed | Boston | Massachusetts | — | — |
| Not listed | Troy | Michigan | — | — |
| Not listed | West Bloomfield | Michigan | — | — |
| Not listed | St Louis | Missouri | — | — |
| Not listed | East Windsor | New Jersey | — | — |
| Not listed | Albuquerque | New Mexico | — | — |
| Not listed | Stony Brook | New York | — | — |
| Not listed | Greer | South Carolina | — | — |
| Not listed | Nashville | Tennessee | — | — |
| Not listed | San Antonio | Texas | — | — |
| Not listed | Salt Lake City | Utah | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00601107, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 4, 2014 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00601107 live on ClinicalTrials.gov.